F M Investments LLC Invests $984,000 in Biohaven Ltd. (NYSE:BHVN)

F M Investments LLC acquired a new position in Biohaven Ltd. (NYSE:BHVN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,338 shares of the company’s stock, valued at approximately $984,000.

A number of other institutional investors also recently bought and sold shares of the stock. Spire Wealth Management bought a new position in shares of Biohaven in the fourth quarter worth about $56,000. Amalgamated Bank raised its position in shares of Biohaven by 21.9% during the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after purchasing an additional 527 shares during the period. US Bancorp DE lifted its stake in shares of Biohaven by 36.7% during the 4th quarter. US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after buying an additional 798 shares in the last quarter. KBC Group NV lifted its stake in shares of Biohaven by 50.1% during the 4th quarter. KBC Group NV now owns 3,377 shares of the company’s stock valued at $126,000 after buying an additional 1,127 shares in the last quarter. Finally, Diversified Trust Co increased its stake in Biohaven by 16.6% in the 4th quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after buying an additional 795 shares in the last quarter. 88.78% of the stock is owned by institutional investors.

Biohaven Stock Up 2.5 %

Biohaven stock opened at $17.55 on Friday. Biohaven Ltd. has a twelve month low of $15.79 and a twelve month high of $55.70. The company’s 50-day moving average price is $30.45 and its 200-day moving average price is $39.57. The company has a market cap of $1.79 billion, a PE ratio of -1.88 and a beta of 1.33.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, sell-side analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director John W. Childs acquired 32,700 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 16.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BHVN. HC Wainwright restated a “buy” rating and issued a $54.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lowered their price target on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Morgan Stanley dropped their price target on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Fourteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $62.77.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.